viewScancell Holdings PLC

Scancell hires two industry veterans as it gears up for the next development phase

The company has brought in outside research and manufacturing expertise

pictured are T-cells attacking a cancer cell
Dr Samantha Paston is a T-cell cloning expert (pictured are T-cells attacking a cancer cell)

Scancell Holdings PLC (LON:SCLP) has made two experienced hires as it gears up for its next phase of development.

T-cell cloning specialist Dr Samantha Paston is the company’s new head of research, while Dr Adrian Parry will take charge of manufacturing.

Paston arrived in mid-January from Oxford-based biotech unicorn Immunocore, where she made “significant contributions” to the company’s current oncology pipeline.

Before joining Immunocore, she held roles at Medigene, Avidex, NIBSC and GlaxoSmithKline. She gained her PhD at University College London.

Parry joins Scancell on February 1 from Mereo BioPharma, where he was head of small molecule chemistry, manufacturing and controls).

He has over two decades’ experience delivering “multiple, complex” drug products.

“We are delighted to welcome both Samantha and Adrian to Scancell,” said chief executive Cliff Holloway.

“Samantha’s experience in T-cell cloning and working with biological molecules, from drug discovery through to early development, will be invaluable as we continue to progress our pipeline of cancer immunotherapies.

“Likewise, Adrian’s 20 years of CMC and GMP development expertise will be key for our manufacturing capabilities moving forward.”

AIM-listed Scancell is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma.

Quick facts: Scancell Holdings PLC

Price: 21 GBX

Market: LSE
Market Cap: £171.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


Scancell Holdings highlights 'most transformative period Scancell has ever...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway talks to Proactive London about the six month period ending ended October 31, 2020, described by Holloway as the 'most transformative period Scancell has ever experienced'. He highlights their strengthened cash position, 'which has allowed us...

on 1/2/21

2 min read